Showing results (1-10 of 252) with videos related to
Sort By:
Pageof 26
Cell Chemical Biology|August 6, 2019
Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small MoleculesRoger S Goody, Matthias P Müller, Daniel RauhRSC Medicinal Chemistry|January 22, 2021
KRasG12C inhibitors in clinical trials: a short historical perspectiveLisa Goebel, Matthias P Müller, Roger S Goody, et al.Small Gtpases|January 6, 2017
Molecular control of Rab activity by GEFs, GAPs and GDIMatthias P Müller, Roger S GoodySmall Gtpases|January 28, 2017
Multivalency in Rab effector interactionsAmrita Rai, Roger S Goody, Matthias P MüllerCell Chemical Biology|January 21, 2018
Try Me: Promiscuous Inhibitors Still Allow for Selective Targeted Protein DegradationMatthias P Müller, Daniel RauhBiochemistry|May 24, 2018
Assays for Nucleotide Competitive Reversible and Irreversible Inhibitors of Ras GTPasesSadasivam Jeganathan, Matthias P Müller, Imtiaz Ali, et al.ACS Chemical Biology|March 17, 2018
Augmented Reality in Scientific Publications-Taking the Visualization of 3D Structures to the Next LevelPatrik Wolle, Matthias P Müller, Daniel RauhJournal of Medicinal Chemistry|April 15, 2024
Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer TherapyTonia Kirschner, Matthias P Müller, Daniel RauhScientific Reports|June 18, 2017
Nucleotide based covalent inhibitors of KRas can only be efficient in vivo if they bind reversibly with GTP-like affinityMatthias P Müller, Sadasivam Jeganathan, Angelika Heidrich, et al.Elife|March 27, 2023
Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitorsLisa Goebel, Tonia Kirschner, Sandra Koska, et al.Pageof 26